List of Excipients in API paltusotine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing paltusotine
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | CELLULOSE, MICROCRYSTALLINE | 2030-09-25 |
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | COPOVIDONE K25-31 | 2030-09-25 |
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | CROSPOVIDONE | 2030-09-25 |
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | FERRIC OXIDE RED | 2030-09-25 |
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | FERRIC OXIDE YELLOW | 2030-09-25 |
| Crinetics Pharmaceuticals Inc | PALSONIFY | paltusotine | 84015-920 | HYPROMELLOSE | 2030-09-25 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for paltusotine
Excipient focus: CELLULOSE, MICROCRYSTALLINE
paltusotine drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
paltusotine drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
paltusotine drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
paltusotine drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
paltusotine drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
paltusotine drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
paltusotine drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
paltusotine drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
paltusotine drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
paltusotine drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
paltusotine drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Crinetics Pharmaceuticals Inc | paltusotine | 84015-920 |
| >Company | >Ingredient | >NDC |
paltusotine drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch